fbpx

Nice | Empagliflozin in Type 2 Diabetes

This is a new guideline from Nice. Empagliflozin is a selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor, which blocks glucose reabsorption in the kidneys and so causes increased urinary excretion. For other SGLT-2 inhibitors have been approved by NICE, see my posts about Dapagliflozin and Canagliflozin.

Empagliflozin use in Type 2 Diabetes

  • as a 2nd drug in combination with metformin if they
    • can not take sulphonylureas.
    • are at significant risk of hypoglycaemia or its consequences.
  • as a 3rd drug with metformin and either a sulphonylurea or a thiazolinedione.
  • in combination with insulin with or without other drugs.

I’m a freelance GP locum in Winchester & Southampton.

Use the NASGP CPD templates to record your reflections.

No Comments Yet.

Leave your comments